Target- |
MechanismPhotosensitizers |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date29 Sep 2016 |
Study of intravenous recombinant human lymphotoxin-α derivative (rhLTα-Da) conbined with cisplatin and 5-Fluorouracil in recurrent and metastatic esophageal cancer
100 Clinical Results associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
100 Deals associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.